Polpharma Biologics Revenue and Competitors

Gdańsk, Poland

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Polpharma Biologics's estimated annual revenue is currently $100.7M per year.(i)
  • Polpharma Biologics's estimated revenue per employee is $77,500

Employee Data

  • Polpharma Biologics has 1299 Employees.(i)
  • Polpharma Biologics grew their employee count by 10% last year.

Polpharma Biologics's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
Chief Staff, Polpharma Biologics Group B.V.Reveal Email/Phone
3
Head CTO OfficeReveal Email/Phone
4
Head QA OperationsReveal Email/Phone
5
VP QualityReveal Email/Phone
6
VP Clinical DevelopmentReveal Email/Phone
7
Head ePlant SystemsReveal Email/Phone
8
Head Quality ComplianceReveal Email/Phone
9
Head MS&TReveal Email/Phone
10
Head Quality Compliance and Quality Systems/QPReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.7M177-12%N/AN/A
#2
$12.1M15621%N/AN/A
#3
$10.7M1388%N/AN/A
#4
$0.3M4-20%N/AN/A
#5
$100.7M129910%N/AN/A
#6
$8.3M1071%N/AN/A
#7
$8.5M1108%N/AN/A
#8
$104.3M8413%N/AN/A
#9
$5.6M7233%N/AN/A
#10
$8.7M11238%N/AN/A
Add Company

What Is Polpharma Biologics?

At Polpharma Biologics we aim at improving patients'​ lives by developing and manufacturing affordable biological medicines, which will broaden access to safe, efficacious we well as innovative therapies for serious diseases. We have created a unique work environment in and around a diverse, international team of experienced professionals and young, talented scientists who share their knowledge and passion to build one of the leading biotech companies in the world. Polpharma Biologics is a biotech company with state-of-the-art facilities across Europe. Operating across international centers of excellence specialized in cell line development, product and process development, clinical manufacturing, commercial scale production and regulatory affairs, allows us to work and partner on our in-house biological pipeline (biosimilars and novelty drugs) and at the same time provide top-quality contract development and manufacturing services to the industry. Our customized CDMO services are available for both biosimilars and innovative molecules, including next-generation biologics. We apply cutting-edge technologies using state-of-the-art mammalian and microbial production equipment. Our wide and integrated competencies give the company a high potential for growth and excellent career opportunities for all employees. Our headquarter is based in Poland – in Gdańsk, beautiful and historic city where you can enjoy Baltic beaches. Check out yourself and join our biomoleCOOL team!

keywords:N/A

N/A

Total Funding

1299

Number of Employees

$100.7M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Polpharma Biologics News

2022-03-30 - Formycon Acquires Assets for Biosimilars Referencing ...

... through a joint venture between ATHOS and Polpharma Biologics; and a 75.1% share of Aristo Pharma, a fully owned subsidiary of ATHOS.